ArticleAsian Pacific journal of cancer prevention : APJCP2025
High Prevalence of EGFR R479K (rs2227983) Polymorphism in Indian Head and Neck Cancer Patients: Association with Unfavourable Clinical Outcome.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe Epidermal Growth Factor Receptor (EGFR) gene, is host to several single nucleotide polymorphisms (SNPs), R497K (rs2227983) is one such example. The current study was conducted to screen a cohort of Indian Head and Neck Squamous Cell Carcinoma patients (HNSCC), for R497K variant of EGFR gene and to correlate effect of the SNP on survival parameters of the cohort.
methodTumour samples were collected from 50 HNSCC patients from Apollo Hospital, Chennai. Genomic DNA from the samples was then extracted by using the high-salt method. The extracted DNA was then screened for EGFR R497K SNP by polymerase chain reaction coupled with restriction fragment length polymorphism (PCR-RFLP) technique. The PCR-RFLP results were then re-confirmed by Sanger sequencing. Then Kaplan-Meier statistical analysis was used to corelate between the SNP data to the survival rates (overall survival (OS) and progression free survival (PFS) of our patients.
resultsOur study found, That among 50 patients 84% (42/50) in the cohort carried this SNP (78% were heterozygous, and 6% were homozygous), and only 16% (8/50) were wild type. Median OS for homozygous, heterozygous and wild type variant were 30.8 months (SE ±3.302; 95% CI: 24.39-37.36), 34.7 months (SE ±2.152; 95% CI: 30.51-38.94), and 41.4 months (SE ±0.511; 95% CI: 39.96-42.37), respectively with p-value of 0.409. Similarly, median PFS for homozygous, heterozygous and wild type variant were 30.0 months (SE ±3.952; 95% CI: 13.08-47.09), 33.5 months (SE ±2.404; 95% CI: 28.66-38.39), and 40.4 months (SE ±1.162; 95% CI: 39.49-41.44) respectively, with 0.553 p-value. Though it is not statistically significant, our study reports a declining trend in the OS and PFS of patients carrying the R497K polymorphism compared to the wild type patients.
conclusionThe SNP R497K of EGFR gene has high prevalence in our Indian study population, which corelates with poor prognosis for HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.